T
Timothy J. Hoffman
Researcher at University of Missouri
Publications - 50
Citations - 2033
Timothy J. Hoffman is an academic researcher from University of Missouri. The author has contributed to research in topics: Gastrin-releasing peptide & In vivo. The author has an hindex of 26, co-authored 50 publications receiving 1950 citations. Previous affiliations of Timothy J. Hoffman include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
TL;DR: This review highlights some of the more recent developments toward design of BBN receptor-specific radiopharmaceuticals that have taken place over the past 2 years.
Journal Article
Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells
Timothy J. Hoffman,Hariprasad Gali,C. Jeffrey Smith,Gary L. Sieckman,Donald L. Hayes,Nellie K. Owen,Wynn A. Volkert +6 more
TL;DR: These studies showed that radiometallated DOTA-X-BBN[7-14]NH(2) constructs with hydrocarbon spacers ranging from 5 to 8 carbon atoms are feasible candidates for further development as diagnostic and therapeutic radiopharmaceuticals for patients with GRP-positive cancers.
Journal ArticleDOI
Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.
TL;DR: This concise review outlines some of the efforts currently underway to develop new GRP receptor specific radiopharmaceuticals by employing a variety of radiometal chelation systems.
Journal Article
Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues.
TL;DR: The compact cyclic structure of 99mTc-CCMSH, its resistance to degradation, and its enhanced intracellular retention are the major contributing factors to the superior in vivo tumor targeting properties of 99tc- CCMSH.
Journal Article
Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3.
C. Jeffrey Smith,Gary L. Sieckman,Nellie K. Owen,Donald L. Hayes,Dana G. Mazuru,Raghuraman Kannan,Wynn A. Volkert,Timothy J. Hoffman +7 more
TL;DR: Results from in vitro and in vivo models demonstrated the ability of (99m)Tc(I)-radiolabled BBN analogues to specifically target GRPrs on human, prostate, cancerous PC-3 cells.